Literature DB >> 22547261

Therapy: Neuroendocrine cancer--are two radionuclides better than one?

Dik J Kwekkeboom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547261     DOI： 10.1038/nrendo.2012.64

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

2.  Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

Authors:  Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

3.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

Authors:  Anna Imhof; Philippe Brunner; Nicolas Marincek; Matthias Briel; Christian Schindler; Helmut Rasch; Helmut R Mäcke; Christoph Rochlitz; Jan Müller-Brand; Martin A Walter
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Authors:  Saima Khan; Eric P Krenning; Martijn van Essen; Boen L Kam; Jaap J Teunissen; Dik J Kwekkeboom
Journal:  J Nucl Med       Date:  2011-07-27       Impact factor: 10.057

5.  90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Authors:  David L Bushnell; Thomas M O'Dorisio; M Sue O'Dorisio; Yusuf Menda; Rodney J Hicks; Eric Van Cutsem; Jean-Louis Baulieu; Francoise Borson-Chazot; Lowell Anthony; Al B Benson; Kjell Oberg; Ashley B Grossman; Mary Connolly; Hakim Bouterfa; Yong Li; Katherine A Kacena; Norman LaFrance; Stanislas A Pauwels
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

7.  Effectiveness of bed rest after mild traumatic brain injury: a randomised trial of no versus six days of bed rest.

Authors:  J R de Kruijk; P Leffers; S Meerhoff; J Rutten; A Twijnstra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

8.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

9.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

Authors:  J A O'Donoghue; M Bardiès; T E Wheldon
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

10.  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Authors:  Jolanta Kunikowska; Leszek Królicki; Alicja Hubalewska-Dydejczyk; Renata Mikołajczak; Anna Sowa-Staszczak; Dariusz Pawlak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.